期刊
STEROIDS
卷 73, 期 1, 页码 59-68出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.steroids.2007.08.014
关键词
hormone replacement therapy; estrogens; estrogen receptor structure; conjugated equine estrogens; Premarin
资金
- NCI NIH HHS [CA089489, P30 CA014599, R01 CA089489-03, R01 CA089489-04, R01 CA089489, R01 CA089489-05, R01 CA089489-01A1, R01 CA089489-02] Funding Source: Medline
- NCRR NIH HHS [P41 RR007707] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA089489, P30CA014599] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR007707] Funding Source: NIH RePORTER
Conjugated equine estrogens (CEEs) are routinely used for hormone replacement therapy (HRT), making it important to understand the activities of individual estrogenic components. Although 17 beta-estradiol (17 beta-E2), the most potent estrogen in CEE, has been extensively characterized, the actions of nine additional less potent estrogens are not well understood. Structural differences between CEEs and 17 beta-E2 result in altered interactions with the two estrogen receptors (ER alpha and ER beta) and different biological activities. To better understand these interactions, we have determined the crystal structure of the CEE analog, 17 beta-methyl-17 alpha-dihydroequilenin (NCI 122), in complex with the ER alpha ligand-binding domain and a peptide from the glucocorticoid receptor-interacting protein 1 (GRIP1) coactivator. NCI 122 has chemical properties, including an unsaturated B-ring and 17 alpha-hydroxyl group, which are shared with some of the estrogens found in CEEs. Structural analysis of the NCI 122-ER alpha LBD-GRIP1 complex, combined with biochemical and cell-based comparisons of CEE components, suggests that factors such as decreased ligand flexibility; decreased ligand hydrophobicity and loss of a hydrogen bond between the 17-hydroxyl group and His524, contribute significantly to the reduced potency of CEEs on ER alpha. (C) 2007 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据